Correction to: 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

December 22/29, 2020 e533 WRITING COMMITTEE MEMBERS* Steve R. Ommen, MD, FACC, FAHA, Chair† Seema Mital, MD, FACC, FAHA, FRCPC, Vice Chair† Michael A. Burke, MD† Sharlene M. Day, MD† Anita Deswal, MD, MPH, FACC, FAHA‡§ Perry Elliott, MD, FRCP, FACC† Lauren L. Evanovich, PhD† Judy Hung, MD, FACC‖ José A. Joglar, MD, FACC, FAHA† Paul Kantor, MBBCh, MSc, FRCPC† Carey Kimmelstiel, MD, FACC, FSCAI† Michelle Kittleson, MD, PhD, FACC† Mark S. Link, MD, FACC¶ Martin S. Maron, MD# Matthew W. Martinez, MD, FACC† Christina Y. Miyake, MD, MS† Hartzell V. Schaff, MD, FACC** Christopher Semsarian, MBBS, PhD, MPH, FAHA† Paul Sorajja, MD, FACC, FAHA, FSCAI††

[1]  B. Maron,et al.  Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. , 2020, Journal of the American College of Cardiology.

[2]  C. Lavie,et al.  Significance of Pulmonary Hypertension in Hypertrophic Cardiomyopathy. , 2020, Current problems in cardiology.

[3]  S. Colan,et al.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.

[4]  E. Ashley,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction , 2020, Circulation.

[5]  M. Landzberg,et al.  Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease. , 2020, American journal of obstetrics and gynecology.

[6]  E. Ashley,et al.  Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. , 2020, JAMA cardiology.

[7]  N. Sreeram,et al.  Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. , 2019, Heart rhythm.

[8]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[9]  S. Ommen,et al.  Conduction Abnormalities and Long-Term Mortality Following Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2019, Journal of the American College of Cardiology.

[10]  B. Wessler,et al.  Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. , 2019, Circulation. Cardiovascular interventions.

[11]  M. Link,et al.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.

[12]  M. Lafreniere-Roula,et al.  Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines? , 2019, European heart journal.

[13]  R. Omar,et al.  A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  M. Link,et al.  Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. , 2019, The American journal of cardiology.

[15]  N. Smedira,et al.  Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. , 2019, The Journal of thoracic and cardiovascular surgery.

[16]  Matthew W. Martinez,et al.  Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association. , 2019, Circulation. Genomic and precision medicine.

[17]  L. Meng,et al.  Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. , 2019, Heart rhythm.

[18]  Joshua L. Deignan,et al.  Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG) , 2019, Genetics in Medicine.

[19]  P. Elliott,et al.  Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives , 2019, Circulation.

[20]  S. Ommen,et al.  Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. , 2019, The Journal of thoracic and cardiovascular surgery.

[21]  B. Maron,et al.  Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". , 2019, Circulation.

[22]  B. Maron,et al.  Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. , 2019, Circulation.

[23]  C. Caleshu,et al.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes , 2019, Circulation. Genomic and precision medicine.

[24]  S. Ommen,et al.  Septal Myectomy in Hypertrophic Cardiomyopathy: National Outcomes of Concomitant Mitral Surgery , 2019, Mayo Clinic proceedings.

[25]  B. Maron,et al.  Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. , 2019, JACC. Clinical electrophysiology.

[26]  S. Ommen,et al.  Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score–matched cohort , 2019, The Journal of thoracic and cardiovascular surgery.

[27]  Joshua L. Deignan,et al.  Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[28]  H. Heidbuchel,et al.  Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). , 2018, European heart journal.

[29]  H. Seggewiss,et al.  Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[30]  G. Lip,et al.  Effectiveness and Safety of Non‐Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study , 2018, Chest.

[31]  E. Nicol,et al.  Heart muscle disease management in aircrew , 2018, Heart.

[32]  B. Maron,et al.  Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[33]  K. Ball,et al.  A Control Theory-Based Pilot Intervention toIncrease Physical Activity in Patients WithHypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[34]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[35]  Amit R. Patel,et al.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy , 2018, Circulation.

[36]  S. Ommen,et al.  Determinants of Reverse Remodeling of the Left Atrium After Transaortic Myectomy. , 2018, The Annals of thoracic surgery.

[37]  N. Smedira,et al.  Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. , 2018, Journal of the American College of Cardiology.

[38]  Marcel E Dinger,et al.  Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[39]  Rajiv Mahajan,et al.  Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis , 2018, European heart journal.

[40]  B. Maron,et al.  Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[41]  M. Chung,et al.  Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review , 2018, Pacing and clinical electrophysiology : PACE.

[42]  R. Oldenburg,et al.  Outcomes of Contemporary Family Screening in Hypertrophic Cardiomyopathy , 2018, Circulation. Genomic and precision medicine.

[43]  J. Minnier,et al.  Standardized Goal‐Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[44]  M. Ackerman,et al.  Return-to-Play for Athletes With Genetic Heart Diseases. , 2018, Circulation.

[45]  K. Aonuma,et al.  Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy and Apical Aneurysm. , 2018, JACC. Clinical electrophysiology.

[46]  M. Sherrid,et al.  Intraoperative Two‐ and Three‐Dimensional Transesophageal Echocardiography in Combined Myectomy‐Mitral Operations for Hypertrophic Cardiomyopathy , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[47]  Harald Becher,et al.  Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[48]  M. Lafreniere-Roula,et al.  Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy , 2018, Clinical genetics.

[49]  I. Olivotto,et al.  Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria. , 2018, Journal of the American College of Cardiology.

[50]  S. Caselli,et al.  Does Sport Participation Worsen the Clinical Course of Hypertrophic Cardiomyopathy? Clinical Outcome of Hypertrophic Cardiomyopathy in Athletes. , 2018, Circulation.

[51]  S. Bowdin,et al.  Clinical genetic testing in pediatric cardiomyopathy: Is bigger better? , 2018, Clinical genetics.

[52]  M. Link,et al.  Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy , 2017, Circulation.

[53]  P. Pellikka,et al.  Comparison of Valsalva Maneuver, Amyl Nitrite, and Exercise Echocardiography to Demonstrate Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.

[54]  B. Maron,et al.  Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.

[55]  Snehal R. Patel,et al.  Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. , 2017, Journal of cardiac failure.

[56]  F. Domínguez,et al.  Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. , 2017, International journal of cardiology.

[57]  A. Keren,et al.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.

[58]  J. Healey,et al.  Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. , 2017, Heart rhythm.

[59]  A. Go,et al.  Comparison of Inappropriate Shocks and Other Health Outcomes Between Single‐ and Dual‐Chamber Implantable Cardioverter‐Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter‐Defibrillators , 2017, Journal of the American Heart Association.

[60]  M. Ackerman,et al.  Competitive Sport Participation Among Athletes With Heart Disease: A Call for a Paradigm Shift in Decision Making. , 2017, Circulation.

[61]  B. Funke,et al.  Pathogenicity of Hypertrophic Cardiomyopathy Variants: A Path Forward Together. , 2017, Circulation. Cardiovascular genetics.

[62]  E. Daoud,et al.  Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator. , 2017, Heart rhythm.

[63]  R. Hall,et al.  Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC) , 2017, European heart journal.

[64]  L. Fauchier,et al.  Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable—Prévention Primaire registry , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[65]  B. Gorenek,et al.  Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Elect , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[66]  A. Wilde,et al.  Penetrance of Hypertrophic Cardiomyopathy in Children Who Are Mutation Positive , 2017, The Journal of pediatrics.

[67]  A. Bogachev-Prokophiev,et al.  Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy , 2017, Journal of Cardiothoracic Surgery.

[68]  Daniel E Forman,et al.  2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[69]  R. Chan,et al.  Discrepant Measurements of Maximal Left Ventricular Wall Thickness Between Cardiac Magnetic Resonance Imaging and Echocardiography in Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Cardiovascular imaging.

[70]  Jeroen J. Bax,et al.  Standards defining a 'Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[71]  D. Corrado,et al.  Accuracy of the ECG for differential diagnosis between hypertrophic cardiomyopathy and athlete’s heart: comparison between the European Society of Cardiology (2010) and International (2017) criteria , 2017, British Journal of Sports Medicine.

[72]  B. Maron,et al.  How to Image Hypertrophic Cardiomyopathy. , 2017, Circulation. Cardiovascular imaging.

[73]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[74]  M. Link,et al.  Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. , 2017, American Journal of Cardiology.

[75]  R. Chan,et al.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients , 2017, Journal of the American Heart Association.

[76]  P. Elliott,et al.  Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis , 2017, European journal of preventive cardiology.

[77]  A. Capucci,et al.  Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT , 2017, European heart journal.

[78]  M. Link,et al.  Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications , 2017, Journal of cardiovascular electrophysiology.

[79]  E. Ashley,et al.  Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial , 2017, JAMA.

[80]  T. Driscoll,et al.  Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. , 2017, Circulation. Cardiovascular genetics.

[81]  Pier D Lambiase,et al.  Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.

[82]  W. Hua,et al.  Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy , 2017, Journal of geriatric cardiology : JGC.

[83]  M. Link,et al.  Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.

[84]  M. Link,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. , 2017, Journal of the American College of Cardiology.

[85]  S. Ommen,et al.  Comparison of Maximal Wall Thickness in Hypertrophic Cardiomyopathy Differs Between Magnetic Resonance Imaging and Transthoracic Echocardiography. , 2017, The American journal of cardiology.

[86]  B. Maron,et al.  Shared decision-making in HCM , 2017, Nature Reviews Cardiology.

[87]  M. Komajda,et al.  Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. , 2017, Archives of cardiovascular diseases.

[88]  C. Autore,et al.  Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy , 2017, Journal of cardiovascular electrophysiology.

[89]  R. Chan,et al.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. , 2016, JACC. Cardiovascular imaging.

[90]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[91]  Steven Swiryn,et al.  Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes , 2016, Circulation.

[92]  S. Ommen,et al.  Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures. , 2016, Journal of the American College of Cardiology.

[93]  C. Autore,et al.  Heart Failure Progression in Hypertrophic Cardiomyopathy - Possible Insights From Cardiopulmonary Exercise Testing. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[94]  T. Aiba,et al.  Single-Coil Defibrillator Leads Yield Satisfactory Defibrillation Safety Margin in Hypertrophic Cardiomyopathy. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[95]  Peter Szolovits,et al.  Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.

[96]  F. Marchlinski,et al.  Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. , 2016, Heart rhythm.

[97]  S. Willems,et al.  High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device , 2016, Journal of cardiovascular electrophysiology.

[98]  P. Noseworthy,et al.  Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation. , 2016, Journal of the American College of Cardiology.

[99]  J. Skinner,et al.  A Prospective Study of Sudden Cardiac Death among Children and Young Adults. , 2016, The New England journal of medicine.

[100]  H. Smeets,et al.  Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. , 2016, European heart journal.

[101]  R. Swaminathan,et al.  Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. , 2016, JAMA cardiology.

[102]  B. Gersh,et al.  Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. , 2016, European heart journal cardiovascular Imaging.

[103]  E. Ashley,et al.  Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy , 2016, Echocardiography.

[104]  P. Lambiase,et al.  Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. , 2016, Heart Rhythm.

[105]  L. Axel,et al.  The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context. , 2016, Journal of the American College of Cardiology.

[106]  B. Gersh,et al.  Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[107]  Yi Shen,et al.  Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[108]  B. Gersh,et al.  The Natural History of Nonobstructive Hypertrophic Cardiomyopathy. , 2016, Mayo Clinic proceedings.

[109]  Stefan L. Zimmerman,et al.  Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography , 2016, The International Journal of Cardiovascular Imaging.

[110]  Jonathan Weinstock,et al.  Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience , 2016, Journal of the American Heart Association.

[111]  I. Moussa,et al.  Usefulness of Von Willebrand Factor Activity Indexes to Predict Therapeutic Response in Hypertrophic Cardiomyopathy. , 2016, The American journal of cardiology.

[112]  Jagmeet P. Singh,et al.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[113]  Zuo-ying Hu,et al.  Efficiencies and Complications of Dual Chamber versus Single Chamber Implantable Cardioverter Defibrillators in Secondary Sudden Cardiac Death Prevention: A Meta-analysis. , 2016, Heart, lung & circulation.

[114]  B. Maron,et al.  Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies , 2016, Circulation.

[115]  P. Elliott,et al.  Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy , 2015, Circulation. Heart failure.

[116]  Laura A. Hatfield,et al.  Transvenous Implantable Cardioverter‐Defibrillator (ICD) Lead Performance: A Meta‐Analysis of Observational Studies , 2015, Journal of the American Heart Association.

[117]  H. Bundgaard,et al.  Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy: A Nationwide Family Study in a Cohort of 3.9 Million Persons , 2015, Circulation.

[118]  N. Smedira,et al.  Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. , 2015, Journal of the American College of Cardiology.

[119]  J. Hung,et al.  Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy , 2015, Current opinion in cardiology.

[120]  Y. Gerber,et al.  Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[121]  R. Omar,et al.  Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA) , 2015, European journal of heart failure.

[122]  N. Smedira,et al.  Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2015, Heart rhythm.

[123]  S. Nagueh,et al.  Role of Imaging in the Evaluation of Patients at Risk for Sudden Cardiac Death: Genotype-Phenotype Intersection. , 2015, JACC. Cardiovascular imaging.

[124]  N. Smedira,et al.  Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. , 2015, Circulation. Cardiovascular imaging.

[125]  J. Carlin,et al.  Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. , 2015, Journal of the American College of Cardiology.

[126]  A. Tajik,et al.  Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy. , 2015, Chest.

[127]  A. Wilde,et al.  Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. , 2015, European heart journal.

[128]  B. Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[129]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[130]  I. Moussa,et al.  Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy‐associated acquired von Willebrand syndrome , 2015, Journal of thrombosis and haemostasis : JTH.

[131]  O. Havndrup,et al.  Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[132]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[133]  D. Babuty,et al.  Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. , 2014, JACC. Heart failure.

[134]  C. Grines,et al.  Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). , 2014, The American journal of cardiology.

[135]  K. Kario,et al.  Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography. , 2014, Journal of cardiology.

[136]  G. Feuchtner,et al.  Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging. , 2014, European journal of radiology.

[137]  W. Roberts,et al.  Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy: Under-Recognized Subset of Candidates for Heart Transplant , 2014, Circulation. Heart failure.

[138]  A. Anastasakis,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[139]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[140]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[141]  Barry J Maron,et al.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.

[142]  D. Pennell,et al.  Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy , 2014, Heart.

[143]  B. Gersh,et al.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High‐Risk Population , 2014, Journal of the American Heart Association.

[144]  R. Zimmer,et al.  Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy. , 2014, Transplantation proceedings.

[145]  P. Agarwal,et al.  Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy. , 2014, The American journal of cardiology.

[146]  P. Lambiase,et al.  Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.

[147]  W. Burchert,et al.  Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients , 2014, The International Journal of Cardiovascular Imaging.

[148]  Daniel E. Singer,et al.  Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices) , 2013, European heart journal.

[149]  R. Frye,et al.  Assessment of coronary artery disease risk in 5463 patients undergoing cardiac surgery: when is preoperative coronary angiography necessary? , 2013, The Journal of thoracic and cardiovascular surgery.

[150]  L. Ferrucci,et al.  Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[151]  C. Semsarian,et al.  Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment , 2013, Genetics in Medicine.

[152]  Dhanunjaya R. Lakkireddy,et al.  Catheter Ablation of Atrial Fibrillation in Hypertrophic Cardiomyopathy: Long-Term Outcomes and Mechanisms of Arrhythmia Recurrence , 2013, Circulation. Arrhythmia and electrophysiology.

[153]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[154]  L. Jordaens,et al.  Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. , 2013, American heart journal.

[155]  V. Korley,et al.  Mexiletine as an Adjunctive Therapy to Amiodarone Reduces the Frequency of Ventricular Tachyarrhythmia Events in Patients With an Implantable Defibrillator , 2013, Journal of cardiovascular pharmacology.

[156]  W. Manning,et al.  Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[157]  N. Smedira,et al.  Predictors of Long-Term Outcomes in Symptomatic Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Relief of Left Ventricular Outflow Tract Obstruction , 2013, Circulation.

[158]  M. Sherrid,et al.  Treatment of Obstructive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy With &bgr;-Blockade or Verapamil , 2013, Circulation. Heart failure.

[159]  B. Maron,et al.  Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. , 2013, The American journal of cardiology.

[160]  M. Link,et al.  Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Long-Term Results of a Prospective Multinational Registry. , 2013, Circulation.

[161]  M. Link,et al.  Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry , 2013, Circulation.

[162]  J. Atherton,et al.  Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy , 2013, Genetics in Medicine.

[163]  M. Link,et al.  Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[164]  E. Argulian,et al.  Antihypertensive therapy in hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[165]  C. Henrikson,et al.  Implanted Defibrillators in Young Hypertrophic Cardiomyopathy Patients: A Multicenter Study , 2013, Pediatric Cardiology.

[166]  S. Ommen,et al.  Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI , 2013, The International Journal of Cardiovascular Imaging.

[167]  K. Muthiah,et al.  Centrifugal Continuous-Flow Left Ventricular Assist Device in Patients With Hypertrophic Cardiomyopathy: A Case Series , 2013, ASAIO journal.

[168]  K. Siminovitch,et al.  Toronto Hypertrophic Cardiomyopathy Genotype Score for Prediction of a Positive Genotype in Hypertrophic Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[169]  P. Lambiase,et al.  A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy , 2013, Heart.

[170]  L. Køber,et al.  Penetrance of Hypertrophic Cardiomyopathy in Children and Adolescents: A 12-Year Follow-up Study of Clinical Screening and Predictive Genetic Testing , 2013, Circulation.

[171]  B. Gersh,et al.  Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2012, Circulation.

[172]  G. Aquaro,et al.  Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. , 2012, Journal of the American College of Cardiology.

[173]  Barry J Maron,et al.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. , 2012, Journal of the American College of Cardiology.

[174]  D. Mancini,et al.  Cardiac transplantation in patients with hypertrophic cardiomyopathy. , 2012, The American journal of cardiology.

[175]  M. Maron,et al.  Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. , 2012, European heart journal.

[176]  M. Yacoub,et al.  Patterns of Disease Progression in Hypertrophic Cardiomyopathy: An Individualized Approach to Clinical Staging , 2012, Circulation. Heart failure.

[177]  Heidi L. Rehm,et al.  Communicating new knowledge on previously reported genetic variants , 2012, Genetics in Medicine.

[178]  Sondra M. Depalma,et al.  Dofetilide Reduces the Frequency of Ventricular Arrhythmias and Implantable Cardioverter Defibrillator Therapies , 2012, Journal of cardiovascular electrophysiology.

[179]  Mike Kirby,et al.  ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy , 2012 .

[180]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[181]  L. Yeates,et al.  The emerging role of the cardiac genetic counselor. , 2011, Heart rhythm.

[182]  C. Semsarian,et al.  Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. , 2011, International journal of cardiology.

[183]  P. Lambiase,et al.  The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy , 2011, Heart.

[184]  K. Bailey,et al.  Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[185]  S. Ommen,et al.  Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. , 2011, JACC. Cardiovascular interventions.

[186]  S. Kushwaha,et al.  Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2011, Circulation. Heart failure.

[187]  R. Hauer,et al.  Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. , 2011, European heart journal.

[188]  M. Gold,et al.  Defibrillation Thresholds in Hypertrophic Cardiomyopathy , 2011, Journal of cardiovascular electrophysiology.

[189]  Vasken Dilsizian,et al.  American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomograph , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[190]  E. Leifer,et al.  Long-Term Follow-Up of Children and Adolescents Diagnosed with Hypertrophic Cardiomyopathy: Risk Factors for Adverse Arrhythmic Events , 2011, Pediatric Cardiology.

[191]  W. Stevenson,et al.  Long-Term Outcomes of Combined Epicardial and Endocardial Ablation of Monomorphic Ventricular Tachycardia Related to Hypertrophic Cardiomyopathy , 2011, Circulation. Arrhythmia and electrophysiology.

[192]  Perry M. Elliott,et al.  Imaging Phenotype Versus Genotype in Hypertrophic Cardiomyopathy , 2011, Circulation. Cardiovascular imaging.

[193]  Andrew S. Mugglin,et al.  Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for Failure: Implications for Patient Management , 2011, Circulation.

[194]  A. Rynkiewicz,et al.  Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. , 2010, European heart journal.

[195]  B. Gersh,et al.  Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[196]  A. Keren,et al.  Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2010, European heart journal.

[197]  L. Køber,et al.  Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[198]  Dhanunjaya R. Lakkireddy,et al.  Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. , 2010, Heart rhythm.

[199]  Barry J Maron,et al.  Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. , 2010, The American journal of cardiology.

[200]  A. Tajik,et al.  Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[201]  A. Angelini,et al.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy , 2010, European heart journal.

[202]  H. Schaff,et al.  Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. , 2010, The Annals of thoracic surgery.

[203]  A. Tajik,et al.  High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[204]  B. Gersh,et al.  Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. , 2009, Journal of the American College of Cardiology.

[205]  W. Manning,et al.  Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.

[206]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[207]  B. Maron,et al.  Successful Catheter Ablation of Hemodynamically Unstable Monomorphic Ventricular Tachycardia in a Patient with Hypertrophic Cardiomyopathy and Apical Aneurysm , 2009, Journal of cardiovascular electrophysiology.

[208]  A. Capucci,et al.  Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events , 2009, Journal of cardiovascular electrophysiology.

[209]  Jeroen J. Bax,et al.  Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. , 2008, JACC. Cardiovascular imaging.

[210]  A. Kadish,et al.  Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. , 2008, Heart rhythm.

[211]  B. Gersh,et al.  Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2008, Circulation.

[212]  P. Lambiase,et al.  Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end‐stage hypertrophic cardiomyopathy , 2008, European journal of heart failure.

[213]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[214]  S. Ommen,et al.  Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[215]  H. Rakowski,et al.  Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail. , 2007, Circulation.

[216]  A. Keren,et al.  Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy , 2007, Heart.

[217]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[218]  Mario J. Garcia,et al.  Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy , 2007, Heart.

[219]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[220]  B. Maron,et al.  Determinants for clinical diagnosis of hypertrophic cardiomyopathy. , 2006, American Journal of Cardiology.

[221]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.

[222]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[223]  W. Bamlet,et al.  Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study , 2006, Circulation.

[224]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[225]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[226]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[227]  W. Mckenna,et al.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy , 2005, Heart.

[228]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[229]  B. Maron,et al.  Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[230]  C. Autore,et al.  The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. , 2005, Journal of the American College of Cardiology.

[231]  B. Maron,et al.  Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[232]  Dick M. Goedhart,et al.  Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. , 2004, Journal of the American College of Cardiology.

[233]  D. Fassbender,et al.  Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[234]  S. Mickelsen,et al.  Doppler Evaluation of the Descending Aorta in Patients with Hypertrophic Cardiomyopathy: Potential for Assessing the Functional Significance of Outflow Tract Gradients and for Optimizing Pacemaker Function , 2004, Journal of Interventional Cardiac Electrophysiology.

[235]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[236]  N. Smedira,et al.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[237]  A. Tajik,et al.  Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease , 2003, Circulation.

[238]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[239]  M. S. Hamid,et al.  Pregnancy related complications in women with hypertrophic cardiomyopathy , 2003, Heart.

[240]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[241]  C. Autore,et al.  Risk associated with pregnancy in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[242]  A. Tajik,et al.  Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. , 2002, The American journal of cardiology.

[243]  M. Chiariello,et al.  Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[244]  N. Smedira,et al.  Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.

[245]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[246]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[247]  B. Maron,et al.  The Electrocardiogram as a Diagnostic Tool for Hypertrophic Cardiomyopathy: Revisited , 2001, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[248]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[249]  L. Faber,et al.  Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[250]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[251]  S. Thanigaraj,et al.  Apical hypertrophic cardiomyopathy: echocardiographic diagnosis with the use of intravenous contrast image enhancement. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[252]  M. Decristofaro,et al.  Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. , 2000, The Canadian journal of cardiology.

[253]  O. Schober,et al.  Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. , 1999, European heart journal.

[254]  U. Gleichmann,et al.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[255]  M. Josephson,et al.  Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). , 1999, Circulation.

[256]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[257]  H. Sugihara,et al.  Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy , 1998, Annals of nuclear medicine.

[258]  B. McCrindle,et al.  Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[259]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[260]  W. Mckenna,et al.  Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. , 1997, European heart journal.

[261]  A. Tajik,et al.  Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. , 1997, Journal of the American College of Cardiology.

[262]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[263]  J. Thomas,et al.  Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy. , 1995, The American journal of cardiology.

[264]  W. Chan,et al.  A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[265]  E. Rosenkranz,et al.  Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[266]  W. Williams,et al.  Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. , 1992, Journal of the American College of Cardiology.

[267]  B. Maron,et al.  Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. , 1989, The American journal of cardiology.

[268]  R. Bonow,et al.  Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. , 1989, Circulation.

[269]  S. Kaplan,et al.  Assessing the Effects of Physician-Patient Interactions on the Outcomes of Chronic Disease , 1989, Medical care.

[270]  J. Gibbs,et al.  Cardiovascular collapse after verapamil in supraventricular tachycardia. , 1987, Archives of disease in childhood.

[271]  M. Webb-Peploe,et al.  Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. , 1986, British heart journal.

[272]  Y. Koga,et al.  Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. , 1986, Japanese heart journal.

[273]  W. Williams,et al.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. , 1985, Progress in cardiovascular diseases.

[274]  J. Dussaule,et al.  Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. , 1985, American heart journal.

[275]  S. Kaplan,et al.  Expanding patient involvement in care. Effects on patient outcomes. , 1985, Annals of internal medicine.

[276]  W. McKenna,et al.  Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. , 1983, Journal of the American College of Cardiology.

[277]  A. Rocchini,et al.  Hemodynamic Effects of Verapamil in Children and Adolescents with Hypertrophic Cardiomyopathy , 1983, Circulation.

[278]  J. Goodwin,et al.  Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. , 1982, British heart journal.

[279]  D M Trandel-Korenchuk,et al.  Patient participation in decision making. , 1982, The Nurse practitioner.

[280]  Michael V. Green,et al.  Effects of Verapamil on Left Ventricular Systolic Function and Diastolic Filling in Patients with Hypertrophic Cardiomyopathy , 1981, Circulation.

[281]  B. Maron,et al.  Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. , 1981, The American journal of cardiology.

[282]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. , 1979, Circulation.

[283]  E. W. Hancock,et al.  Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. , 1973, The American journal of cardiology.

[284]  T. Nealon The American Association for Thoracic Surgery , 1972 .

[285]  R. Gramiak,et al.  Long-term propranolol therapy in muscular subaortic stenosis. , 1970, British heart journal.

[286]  E. Braunwald,et al.  Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.

[287]  E. Braunwald,et al.  Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. , 1962, The American journal of cardiology.

[288]  C. Rooryck,et al.  Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study , 2018, European heart journal cardiovascular Imaging.

[289]  T. Edvardsen,et al.  Vigorous exercise in patients with hypertrophic cardiomyopathy. , 2018, International journal of cardiology.

[290]  N. Smedira,et al.  CONGENITAL : HYPERTROPHIC CARDIOMYOPATHY Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy : Potential for refinement of current criteria , 2018 .

[291]  D. Theuns,et al.  Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.

[292]  B. Gersh,et al.  Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[293]  H. Calkins,et al.  2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Journal of the American College of Cardiology.

[294]  L. Eckardt,et al.  Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience , 2015, Clinical Research in Cardiology.

[295]  DanielePasqualucci,et al.  Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy , 2015 .

[296]  N. Smedira,et al.  Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. , 2014, JACC. Cardiovascular imaging.

[297]  C. Vosa,et al.  Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. , 2013, The Journal of thoracic and cardiovascular surgery.

[298]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[299]  M. Cheitlin Long-Term Survival in Patients With Resting Obstructive Hypertrophic Cardiomyopathy: Comparison of Conservative Versus Invasive Treatment , 2012 .

[300]  P. Pieper,et al.  Pregnancy in women with hypertrophic cardiomyopathy , 2012, Netherlands Heart Journal.

[301]  M. Sherrid,et al.  Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[302]  J. Stockman Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy , 2011 .

[303]  E. Fain,et al.  Comparison of (cid:1) -Blockers, Amiodarone Plus (cid:1) -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators The OPTIC Study: A Randomized Trial , 2005 .

[304]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[305]  S H Kaplan,et al.  Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. , 1988, Journal of general internal medicine.

[306]  John E. Ware,et al.  Expanding Patient Involvement in Care , 1985 .